chemotherapy

CORRECTION

Open Access



Pengcheng Xu^{1†}, Ru Wang^{1,2†}, Wenqian Yang¹, Yanyan Liu¹, Dongsheng He¹, Zixuan Ye¹, Daquan Chen³, Yuan Ding¹, Jiasheng Tu^{1*} and Yan Shen^{1*}[®]

Correction to: J Nanobiotechnol (2021) 19:77 https://doi.org/10.1186/s12951-021-00824-5

Following publication of the original article [1], the authors identified inadvertent errors in Fig. 9a. Errors in the merged images of the DM1-mPEG/HER-PGNSs group and the DM1-mPEG/HER-PGNSs+NIR group, being in reverse order were found, which were possibly made during image compilation. The corrected Fig. 9 and the corrected figure caption are given below. The correction of these figures does not affect the results and

conclusion. All authors agree to these corrections and apologize for these errors.

The incorrect and correct Figure 9 are published in this Correction article. The original article has been updated.

Figure 9 before correction: (Fig. 9a contained an error caused by the reverse order before submission):

The original article can be found online at https://doi.org/10.1186/s12951-021-00824-5.

*Correspondence: jiashengtu@cpu.edu.cn; shenyan@cpu.edu.cn

[†]Pengcheng Xu and Ru Wang contributed equally to this work ¹ Department of Pharmaceutics, China Pharmaceutical University,

Nanjing, China

Full list of author information is available at the end of the article



© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativeco mmons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/ zero/1.0/ apolies to the data made available in this article, unless otherwise stated in a credit line to the data.



assay of apoptosis in tumours and the immunofluorescent detection of tubulin, cleaved-caspase3 and HSP70; **b**, **c** apoptosis cell counts of TUI and IOD value of tubulin, cleaved-caspase 3 and HSP70; **d**, **e** Effect of NIR treatment on the inhibition of tumour-associated macrophages M2 polarization by western blotting; and **f-h** The immunohistological staining of CD206 in tumours. (**p < 0.01, ***p < 0.001)



Fig. 9 Apoptosis mechanism related protein detected by western blotting, immunofluorescence and immunohistological staining. **a** TUNEL assay of apoptosis in tumours and the immunofluorescent detection of tubulin, cleaved-caspase3 and HSP70; **b**, **c** apoptosis cell counts of TUNEL and IOD value of tubulin, cleaved-caspase 3 and HSP70; **d**, **e** Effect of NIR treatment on the inhibition of tumour-associated macrophages M2 polarization by western blotting; and **f-h** The immunohistological staining of CD206 in tumours. (**p < 0.01, ***p < 0.001)

Corrected Fig. 9:

Author details

¹Department of Pharmaceutics, China Pharmaceutical University, Nanjing, China. ²Chia-Tai Tianqing Pharmaceutical Group Co. Ltd., Nanjing, China. ³School of Pharmacy, Yantai University, Yantai 264005, China.

Published online: 27 April 2021

Reference

 Xu P, Wang R, Yang W, Liu Y, He D, Ye Z, Chen D, Ding Y, Tu J, Shen Y. A DM1-doped porous gold nanoshell system for NIR accelerated redox-responsive release and triple modal imaging guided photothermal synergistic chemotherapy. Journal of Nanobiotechnology. 2021;19(1):77–77.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

